Bioventus entered into a multi-year agreement with Institut Biochimique, gaining exclusive U.S. distribution rights for GELSYN-3™ 3-injection hyaluronic acid product for pain relief associated with knee osteoarthritis. Bioventus plans to launch GELSYN-3 in 3Q16.
The agreement supports Bioventus’ intent to position itself as an orthobiologics leader. Other entities that compete in the 3-injection space, as summarized in the relevant product landscape in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT, include Anika, Ferring, Sanofi, Tribute Pharmaceuticals, etc.
Bioventus entered into a multi-year agreement with Institut Biochimique, gaining exclusive U.S. distribution rights for GELSYN-3™ 3-injection hyaluronic acid product for pain relief associated with knee osteoarthritis. Bioventus plans to launch GELSYN-3 in 3Q16.
Bioventus entered into a multi-year agreement with Institut Biochimique, gaining exclusive U.S. distribution rights for GELSYN-3™ 3-injection hyaluronic acid product for pain relief associated with knee osteoarthritis. Bioventus plans to launch GELSYN-3 in 3Q16.
The agreement supports Bioventus’ intent to position itself as an orthobiologics leader. Other entities that compete in the 3-injection space, as summarized in the relevant product landscape in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT, include Anika, Ferring, Sanofi, Tribute Pharmaceuticals, etc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
